Nanochanneled device and related methods
Inventors
Ferrari, Mauro • Liu, Xuewu • Grattoni, Alessandro • Goodall, Randy • Hudson, Lee
Assignees
University of Texas System • Nanomedical Systems Inc • Ohio State University Research Foundation
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-8632510-B2
Publication Date
2014-01-21
Expiration Date
Abstract
A capsule configured for in vivo refilling of a thereapeutic agent. In certain embodiments, the capsule may contain methotrexate.
Core Innovation
The disclosed invention provides a capsule that includes a nanochannel delivery device and a bladder located within the capsule. The bladder contains molecules of a therapeutic agent, and the nanochannel delivery device is configured to control a diffusion rate of the molecules of the therapeutic agent from the bladder.
The capsule includes a first port and a second port, where the first port extends through the capsule and bladder and the second port extends through the capsule but does not extend through the bladder. This port arrangement supports an in vivo refilling architecture in which a refill mechanism is provided while defining which internal structures are penetrated.
The disclosed capsule architecture further includes septa configured for needle puncture, including self-sealing material for the septum(s). The partial content also describes nanochanneled therapeutic delivery using horizontal nanochannel layouts and silicon microfabrication, including single-layer and multilayer sandwich structures, with inlet and outlet microchannels in direct fluid communication with nanochannels.
Claims Coverage
Independent claim clm-00001 recites a capsule apparatus with 2 inventive features: a bladder filled with therapeutic-agent molecules and a nanochannel delivery device configured to control diffusion rate from the bladder, together with a two-port architecture with different penetration extents into the bladder.
Capsule with bladder and nanochannel delivery device controlling diffusion rate
A capsule comprises a nanochannel delivery device and a bladder located within the capsule, where the bladder contains molecules of a therapeutic agent and the nanochannel delivery device is configured to control a diffusion rate of the molecules of the therapeutic agent from the bladder.
Two-port architecture with different bladder penetration extents
A first port extends through the capsule and bladder, and a second port extends through the capsule but does not extend through the bladder.
The core inventive combination is diffusion-rate-controlled delivery of therapeutic-agent molecules from an internal bladder via a nanochannel delivery device, together with a first/second port arrangement that distinguishes whether the port extends into the bladder. Dependent claim members refine the nanochannel delivery device microchannel connectivity and planar body arrangement, constrain port accessibility and alignment for in vivo implantation, and add needle puncture and self-sealing septa.
Stated Advantages
Provides a continuous, predictable therapeutic-agent release by controlling a diffusion rate of molecules from the bladder.
Documented Applications
In vivo refilling of a capsule-based nanochannel therapeutic delivery device using a first port extending through the capsule and bladder and a second port extending through the capsule but not through the bladder.
Interested in licensing this patent?